Interim VeinViewer Study at Mercy Hospital Shows Greater Than 30 Percent Reduction in Medically Unnecessary PICC Placements in

  Interim VeinViewer Study at Mercy Hospital Shows Greater Than 30 Percent
  Reduction in Medically Unnecessary PICC Placements in Neonatal Intensive
  Care Unit

Business Wire

MEMPHIS, Tenn. -- October 16, 2013

Christie Medical Holdings, Inc., a global leader in mobile vascular imaging
systems, and Mercy Hospital Oklahoma City today announced the completion of a
210-patient prospective clinical study in the health center’s Neonatal
Intensive Care Unit (NICU). The study evaluates whether using VeinViewer®
impacts the rates of medically unnecessary PICC placements and the number of
attempts to insert peripheral intravenous (PIV) catheters.

“Even with a new facility, increased patient census, more nurses and formal
training on manual placement of IVs, the NICU department prior to the study
faced high rates of IV attempts per patient and a high level of medically
unnecessary PICCs. We wanted to improve our rates to deliver better patient
care and implementing VeinViewer is one way we are doing this,” said Michele
McEver, NICU nurse manager at Mercy Hospital Oklahoma City.

Prior to the study, Mercy Hospital Oklahoma City’s NICU department documented
a baseline of non-VeinViewer vascular access experiences and estimated the
average to be 5.2 IV sticks per child with some children having double-digit
attempts. The baseline rate of medically unnecessary PICCs was one for every
13 patients (1:13).

An analysis of data from the first 100 patients showed the number of IV sticks
per child dropped from 5.2 to 3.1 with the use of VeinViewer. Similarly, the
ratio of medically unnecessary PICCs decreased from 1:13 to 1:25, a 48%
reduction. The data from this interim analysis was presented in San Antonio,
Texas at the Association for Vascular Access (AVA) meeting in October 2012.

“We were pleased with the interim results that saw a significant decrease in
both medically unnecessary PICC lines and peripheral IVs,” said Dawn Norman,
director of regulatory, quality and clinical affairs for Christie. “Not only
does VeinViewer make it much easier to find the extremely difficult veins in
babies, but relieves them from some discomfort and pain, which is very
important to us. We look forward to the release of the final results.”

“There is a great potential for return on investment with the average cost per
PICC line, including materials and cost to place it, of about $700,” noted
Chris Schnee, general manager and vice president of sales and marketing at
Christie. “This interim analysis demonstrates VeinViewer’s ability to decrease
unnecessary PICCs by at least 30 percent and is the only platform of products
on the market that has proven this critical result. With the CMS ruling that
secondary, nosocomial catheter related blood stream infections (CLBSI) are non
reimbursable, the simplest method to reduce the potential risk and compounded
cost of such events is to directly reduce the number of medically unneeded
PICCs lines. Only VeinViewer can provide pre-, during and post-access benefits
throughout the entire vascular access procedure and has been shown through
clinical studies to increase both first stick success and patient satisfaction
up to 100%.

VeinViewer Technology Backed by Christie’s Long History of Technical

VeinViewer technology was developed with the aid of the engineering
capabilities and resources of parent company Christie Digital Systems, a
leading global visual technology firm with more than 80 years of experience in
the projection systems industry. VeinViewer is the first and only device on
the market to use: harmless near-infrared light, DLP^® technologies, exclusive
technology such as Active Vascular Imaging Navigation (AVIN™) providing the
demanded Pre, During and Post-access (PDP) benefits, TrueView imaging accuracy
in projected vein-widths which is three to ten times more accurate than
competition, and technologies such as Df2 (Digital full field) to illuminate
the only real-time HD digital image of subcutaneous vasculature and blood
patterns directly onto the skin surface. Although designed for assistance in
IV starts and blood draws, VeinViewer has proven beneficial in spider and
varicose vein treatment.

To learn more about Christie product offerings: VeinViewer Vision, VeinViewer
VisionXTND and VeinViewer Flex, please visit

About Mercy

Mercy is the sixth largest Catholic health care system in the U.S. and serves
more than 3 million people annually. Mercy includes 32 hospitals, 300
outpatient facilities, 39,000 co-workers and more than 2,000 integrated
physicians in Arkansas, Kansas, Missouri and Oklahoma. Mercy also has outreach
ministries in Louisiana, Mississippi and Texas.

About Christie Medical Holdings, Inc.

Christie Medical Holdings Inc. is a global company based in Memphis, Tenn.,
that discovers, develops and commercializes medical technologies. The
company’s market-leading product, VeinViewer, is a mobile vascular imaging
system that allows health care providers to clearly see accessible vasculature
as a real time HD image, directly on the surface of the skin. Christie Medical
Holdings Inc. is owned by Christie Digital Systems Inc., a global visual
technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more
information on Christie Digital Systems or Christie Medical Holdings, visit

Follow us on Twitter @veinviewer

Christie® is a trademark of Christie Digital Systems USA, Inc., registered in
the United States of America and certain other countries.

DLP® is a registered trademark of Texas Instruments.


Christie Medical Holdings, Inc.
Carmen Robert, 519-572-5824
Christie Public Relations
Press spacebar to pause and continue. Press esc to stop.